Arch Therapeutics Inc
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and… Read more
Arch Therapeutics Inc (ARTH) - Total Assets
Latest total assets as of June 2024: $1.40 Million USD
Based on the latest financial reports, Arch Therapeutics Inc (ARTH) holds total assets worth $1.40 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arch Therapeutics Inc - Total Assets Trend (2013–2023)
This chart illustrates how Arch Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Arch Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (September 2023)
Arch Therapeutics Inc's total assets of $1.40 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $1.36 Million | 69.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2023)
This chart illustrates how Arch Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arch Therapeutics Inc's current assets represent 99.6% of total assets in 2023, an increase from 99.4% in 2013.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2023, down from 35.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 69.7% of total assets.
Arch Therapeutics Inc Competitors by Total Assets
Key competitors of Arch Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Arch Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Arch Therapeutics Inc generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Arch Therapeutics Inc is currently not profitable relative to its asset base.
Arch Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 0.16 | 4.05 |
| Quick Ratio | 0.01 | 0.02 | 3.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-12.57 Million | $ -8.02 Million | $ 2.18 Million |
Arch Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Arch Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 34.61 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -24.8% |
| Total Assets | $1.96 Million |
| Market Capitalization | $923.89K USD |
Valuation Analysis
Below Book Valuation: The market values Arch Therapeutics Inc's assets below their book value (0.47 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Arch Therapeutics Inc's assets decreased by 24.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arch Therapeutics Inc (2013–2023)
The table below shows the annual total assets of Arch Therapeutics Inc from 2013 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-09-30 | $1.96 Million | -24.79% |
| 2022-09-30 | $2.60 Million | -29.18% |
| 2021-09-30 | $3.68 Million | +70.92% |
| 2020-09-30 | $2.15 Million | -25.88% |
| 2019-09-30 | $2.90 Million | -40.04% |
| 2018-09-30 | $4.84 Million | -20.53% |
| 2017-09-30 | $6.09 Million | +18.39% |
| 2016-09-30 | $5.14 Million | +28.51% |
| 2015-09-30 | $4.00 Million | +356.45% |
| 2014-09-30 | $876.99K | -44.75% |
| 2013-09-30 | $1.59 Million | -- |